Allogene Therapeutics
Pratiksha Dighe is a skilled scientist specializing in solid tumors at Allogene Therapeutics since October 2022. Prior experience includes serving as a Research Associate Supervisor at Cpmc Research Institute, where involvement in the Cancer Avatar Project focused on glioblastomas and patient-derived xenograft (PDX) mouse models. Previous roles include Senior Research Associate and Lab Manager at the Buck Institute for Research on Aging, with research concentrated on mitochondria and reactive oxygen species in aging and disease, as well as internships and volunteer work at UC Davis MIND Institute involving in utero animal surgeries and molecular development studies. Pratiksha holds a Master’s Degree in Biological Sciences with a concentration in Stem Cell Biology from California State University-Sacramento and a B.Tech in Biotechnology from Padmashree Dr. D Y Patil University, complemented by a Certificate in Clinical Research Conduct and Management from UC Berkeley Extension.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.